Futura Medical plc has announced that its product Eroxon® is now available for purchase online through the BinSina Pharmacy in the United Arab Emirates (UAE). This marks the first market in the Middle East to stock the product. Eroxon® is a clinically proven topical treatment for adult men with erectile dysfunction. It is FDA approved in the US, CE marked in Europe, and UKCA marked in the UK. The product is known for its key claim of "Helps you get an erection within 10 minutes." Eroxon® is the agreed brand name in certain regions such as the EU, while MED3000 is the internal code name used by the company and in reference to countries where regulatory approval or commercial distribution agreements have not yet been achieved.
Futura Medical is a pharmaceutical company that develops innovative products based on its proprietary transdermal DermaSys® technology. Each DermaSys® formulation is separately patented and tailored for the selected indication and application. The company's products are developed for the prescription and consumer healthcare markets. Futura Medical's flagship product, MED3000, is a topical gel formulation that provides a novel treatment for erectile dysfunction through a unique evaporative mode of action. The company has conducted two Phase 3 studies using MED3000, which demonstrated its effectiveness as a clinically proven treatment for ED with a rapid speed of onset and a favorable benefit versus risk profile.
Futura Medical is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.